(0.25%) 5 144.25 points
(0.14%) 38 496 points
(0.41%) 17 919 points
(-0.72%) $83.25
(2.13%) $1.964
(-0.16%) $2 343.50
(-0.09%) $27.51
(2.80%) $947.95
(-0.05%) $0.934
(-0.06%) $11.02
(-0.27%) $0.798
(1.88%) $93.60
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.62%
@ $36.11
发出时间: 15 Feb 2024 @ 02:49
回报率: 0.54%
上一信号: Feb 14 - 01:40
上一信号:
回报率: 0.46 %
Live Chart Being Loaded With Signals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases...
Stats | |
---|---|
今日成交量 | 324 978 |
平均成交量 | 937 108 |
市值 | 2.39B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.670 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.43 |
ATR14 | $0.0280 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Jimenez Freddy A. | Buy | 20 000 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Buy | 4 166 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Sell | 4 166 | Incentive Stock Option (Right to Buy) |
2024-02-13 | Jimenez Freddy A. | Sell | 20 000 | Incentive Stock Option (Right to Buy) |
2024-01-02 | Martin Samuel Bates | Buy | 10 750 | Common Stock |
INSIDER POWER |
---|
75.21 |
Last 97 transactions |
Buy: 2 900 849 | Sell: 507 801 |
音量 相关性
Celldex Therapeutics Inc 相关性 - 货币/商品
Celldex Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $6.88M |
毛利润: | $3.88M (56.30 %) |
EPS: | $-2.92 |
FY | 2023 |
营收: | $6.88M |
毛利润: | $3.88M (56.30 %) |
EPS: | $-2.92 |
FY | 2022 |
营收: | $2.36M |
毛利润: | $957 000 (40.60 %) |
EPS: | $-2.62 |
FY | 2021 |
营收: | $4.65M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.640 |
Financial Reports:
No articles found.
Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。